These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27677349)

  • 1. Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact.
    Voznesensky I; DeLay KJ; Hellstrom WJ
    Expert Opin Pharmacother; 2016 Dec; 17(17):2281-2289. PubMed ID: 27677349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases.
    Cai Z; Zhang J; Li H
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):119-128. PubMed ID: 30675707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
    Yafi FA; Sharlip ID; Becher EF
    Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future is today: emerging drugs for the treatment of erectile dysfunction.
    Albersen M; Shindel AW; Mwamukonda KB; Lue TF
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):467-80. PubMed ID: 20415601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular diseases and erectile dysfunction].
    Pomeshkina SA; Pomeshkin EV; Barbarash OL; Neĭmark AI
    Ter Arkh; 2010; 82(10):37-40. PubMed ID: 21341462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of erectile dysfunction and peculiarities of its treatment in men with high cardiovascular risk].
    Mamedov MN; Digigova RT; Sharvadze GG; Ugurchieva ZO; Kovrigina MN; Stroeva MV
    Kardiologiia; 2010; 50(11):85-90. PubMed ID: 21526570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of the association between erectile dysfunction and cardiovascular disease.
    Gandaglia G; Briganti A; Jackson G; Kloner RA; Montorsi F; Montorsi P; Vlachopoulos C
    Eur Urol; 2014 May; 65(5):968-78. PubMed ID: 24011423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for the treatment of erectile dysfunction.
    Peak TC; Yafi FA; Sangkum P; Hellstrom WJ
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):263-75. PubMed ID: 25740087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and Therapeutic Implications of Erectile Dysfunction in Patients with Cardiovascular Disease.
    Gandaglia G; Briganti A; Montorsi P; Mottrie A; Salonia A; Montorsi F
    Eur Urol; 2016 Aug; 70(2):219-22. PubMed ID: 26873841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erectile dysfunction and cardiovascular disease.
    Menezes A; Artham S; Lavie CJ; Milani RV; O'Keefe J
    Postgrad Med; 2011 May; 123(3):7-16. PubMed ID: 21566411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer phosphodiesterase inhibitors: comparison with established agents.
    McNamara ER; Donatucci CF
    Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
    Imprialos K; Koutsampasopoulos K; Manolis A; Doumas M
    Curr Vasc Pharmacol; 2021; 19(3):301-312. PubMed ID: 32286949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of phosphodiesterase-5 inhibitors for treating erectile dysfunction in kidney transplant recipients: a meta-analysis.
    Fanbin L; Mei Y; Yan Z; Yirong Y; Shaoling Z; Yong C; Peng X
    Exp Clin Transplant; 2014 Jun; 12(3):184-9. PubMed ID: 24907716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
    Basal S; Wambi C; Acikel C; Gupta M; Badani K
    BJU Int; 2013 Apr; 111(4):658-65. PubMed ID: 23186312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the drug safety of treating erectile dysfunction.
    Gul M; Serefoglu EC
    Expert Opin Drug Saf; 2019 Oct; 18(10):965-975. PubMed ID: 31433252
    [No Abstract]   [Full Text] [Related]  

  • 19. A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder.
    Kennedy SH; Dugré H; Defoy I
    Int Clin Psychopharmacol; 2011 May; 26(3):151-8. PubMed ID: 21471773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avanafil - a further step to tailoring patient needs and expectations.
    Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.